2. Search Result
Search Result
Results for "

cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)

" in MedChemExpress (MCE) Product Catalog:

205

Inhibitors & Agonists

239

Peptides

27

Natural
Products

4

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-P0023
    Cyclo(-RGDfK)
    25+ Cited Publications

    		 Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK)
  • HY-100563A
    Cyclo(RGDyK)
    4 Publications Verification

    		 Integrin Cancer
    Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
    Cyclo(RGDyK)
  • HY-P1934A
    Cyclo(L-Phe-L-Pro)

    		Fungal Bacterial IFNAR Reactive Oxygen Species (ROS) Infection Inflammation/Immunology Cancer
    Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide . Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation . Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay .
    Cyclo(L-Phe-L-Pro)
  • HY-P3366
    Ecnoglutide

    XW003

    		 GCGR Metabolic Disease
    Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .
    Ecnoglutide
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    2 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-P11274A
    Zenagamtide sodium

    Amycretin sodium; NN 9487 sodium

    		 Amylin Receptor Insulin Receptor GCGR Metabolic Disease
    Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
    Zenagamtide sodium
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    25+ Cited Publications

    		 Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    Cyclo(-RGDfK) TFA
  • HY-P1934
    Cyclo(Phe-Pro)
    5+ Cited Publications

    cyclo(PhenylAlanylprolyl); A-64863

    		 HCV Bacterial Antibiotic Reactive Oxygen Species (ROS) Infection
    Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) is a quorum-sensing molecule of Vibrio vulnificus that specifically interacts with RIG-I, inhibiting RIG-I polyubiquitination, suppressing IRF-3 activation, and reducing type I interferon production. Cyclo(Phe-Pro) enhances susceptibility to HCV and influenza virus and also alleviates plant aluminum toxicity stress. The mechanism of Cyclo(Phe-Pro) involves the regulation of host immune signaling pathways, bacterial virulence gene expression, and plant antioxidant systems, making it a promising candidate for research in viral infections, bacterial virulence regulation, and agricultural stress resistance .
    Cyclo(Phe-Pro)
  • HY-P10956
    Colulintide

    LY3541105

    		 Amylin Receptor CGRP Receptor Metabolic Disease
    Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity .
    Colulintide
  • HY-139741
    cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)

    		DNA/RNA Synthesis Others
    cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc) provides an avenue for developing a nonhormonal male contraceptive by blocking of GRTH/DDX25 phosphorylation.
    cyclo(Phe-Ala-Gly-Arg-Arg-Arg-Gly-AEEAc)
  • HY-101402
    Cyclo(his-pro)

    Cyclohistidyl-proline; Histidylproline diketopiperazine

    		 NF-κB Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Cyclo(his-pro) (Cyclo(histidyl-proline)) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone . Cyclo(his-pro) could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) can cross the brain-blood-barrier and affect diverse inflammatory and stress responses .
    Cyclo(his-pro)
  • HY-P1938
    Cyclo(L-Pro-L-Val)

    		Bacterial Infection Inflammation/Immunology
    Cyclo(L-Pro-L-Val) is an antimicrobial and anti-inflammatory agent. Cyclo(L-Pro-L-Val) has toxic activity against plant pathogens such as R. fascians LMG 3605, and its potency may be comparable to that of Chloramphenicol (HY-B0239). Cyclo(L-Pro-L-Val) can inhibit the phosphorylation of IKKα, IKKβ, NF-κB, etc., and the activation of iNOS and COX-2, thereby exerting anti-inflammatory activity. Cyclo(L-Pro-L-Val) can be used in the research of biopesticides in the agricultural field, as well as in the research of inflammation-related diseases .
    Cyclo(L-Pro-L-Val)
  • HY-P5712
    Gramicidin S
    1 Publications Verification

    Gramicidin soviet

    		 Antibiotic Bacterial Na+/K+ ATPase Infection
    Gramicidin S (Gramicidin soviet) is a cationic cyclic peptide antibiotic that selectively targets bacterial cell membranes and has anticancer activity. Gramicidin S also exerts antibacterial activity by destroying membrane integrity and interfering with membrane protein function. Gramicidin S inserts into the phospholipid bilayer through hydrophobic amino acid residues, specifically binds to negatively charged membrane lipids and disrupts membrane structure, thereby inhibiting cell division and cell wall synthesis, and ultimately causing bacterial death. Gramicidin S also inhibits ion channels, with IC50s of 41 μM, 24 μM, and 3 μM for Na +/K +-ATPase, tobacco leaf plasma membrane Mg 2+/K +-ATPase, and rat heart plasma membrane Ca 2+-ATPase, respectively .
    Gramicidin S
  • HY-P11274
    Zenagamtide

    Amycretin; NN 9487

    		 Amylin Receptor GCGR Insulin Receptor Metabolic Disease
    Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
    Zenagamtide
  • HY-100563
    Cyclo(RGDyK) trifluoroacetate
    4 Publications Verification

    		 Integrin Cancer
    Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
    Cyclo(RGDyK) trifluoroacetate
  • HY-P10304
    Cyclo(Arg-Pro)

    Cyclo(Pro-Arg)

    		 Fungal Others
    Cyclo(Arg-Pro) (Cyclo(Pro-Arg)) is an inhibitor for chitinase. Cyclo(Arg-Pro) inhibits cell separation of Saccharomyces cerevisiae, without affecting its growth. Cyclo(Arg-Pro) inhibits the morphological change of Candida albicans from yeast form to filamentous form .
    Cyclo(Arg-Pro)
  • HY-P11285A
    LAGIPRA peptide TFA

    Long acting GIPRA-1 TFA

    		 Insulin Receptor Metabolic Disease
    LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes .
    LAGIPRA peptide TFA
  • HY-P11271
    Ribupatide

    		Insulin Receptor GLP Receptor Metabolic Disease
    Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
    Ribupatide
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-P10856
    CPI1

    		P-glycoprotein Cancer
    CPI1 is a multidrug resistance protein 1 (MRP1) inhibitor with a Ki value of 100 nM. CPI1 binds to the same substrate-binding site as leukotriene C4, stabilizes MRP1 in an apo-like inward-facing conformation, blocks the conformational changes required for ATP hydrolysis and substrate transport, and inhibits the ATPase activity of human and bovine MRP1. CPI1 serves as a tool for investigating the substrate transport mechanism of MRP1. CPI1 is applicable to research related to cancer multidrug resistance .
    CPI1
  • HY-P1613A
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

    Cyclo(RGDfV) TFA; C(RGDfV) TFA

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
  • HY-P0231
    AZP-531
    2 Publications Verification

    		 GHSR Metabolic Disease Endocrinology
    AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.
    AZP-531
  • HY-107245
    Segetalin B
    2 Publications Verification

    		 Estrogen Receptor/ERR Sirtuin RUNX Metabolic Disease
    Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
    Segetalin B
  • HY-126810A
    NP213 TFA

    		Fungal Infection
    NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections .
    NP213 TFA
  • HY-P1676
    cyclo(RLsKDK)
    2 Publications Verification

    BK-1361

    		 MMP Cancer
    cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer .
    cyclo(RLsKDK)
  • HY-P10269
    Bofanglutide

    GZR18

    		 GLP Receptor Metabolic Disease
    Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC50 of 0.677 nM. GZR18 ameliorates type 2 diabetes .
    Bofanglutide
  • HY-P10426
    cyclo(CLLFVY)

    		HIF/HIF Prolyl-Hydroxylase VEGFR Cancer
    cyclo(CLLFVY) is an inhibitor for hypoxia inducible factor-1 (HIF-1), with IC50 of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .
    cyclo(CLLFVY)
  • HY-101402A
    Cyclo(his-pro) TFA

    Cyclohistidyl-proline TFA; Histidylproline diketopiperazine TFA

    		 NF-κB Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone . Cyclo(his-pro) TFA could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) TFA can cross the brain-blood-barrier and affect diverse inflammatory and stress responses .
    Cyclo(his-pro) TFA
  • HY-P5314
    OK2

    		EGFR STAT Others
    OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .
    OK2
  • HY-P10221A
    Cyclo(CKLIIF) TFA

    		HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo(CKLIIF) TFA is an inhibitor of HIF-1α and HIF-2α. The KD values of Cyclo(CKLIIF) TFA for the PAS-B domains of HIF1-α and HIF2-α are 2.6 μM and 2.2 μM, respectively. Cyclo(CKLIIF) TFA disrupts the protein-protein interaction between HIF-1α and HIF-1β. Cyclo(CKLIIF) TFA can be used in cancer research .
    Cyclo(CKLIIF) TFA
  • HY-75564
    Cyclo(Ala-Gly)

    		Endogenous Metabolite Cancer
    Cyclo(Ala-Gly), a metabolite of a mangrove endophytic fungus, Penicillium thomi, exhibits cytotoxicity against A549, HepG2 and HT29 cells. The IC50 values range from 9.5 to 18.1 μM .
    Cyclo(Ala-Gly)
  • HY-P10377
    GUB03385

    		Neuropeptide FF Receptor Metabolic Disease
    GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC50: 0.4 nM) and NPFF2R (partial agonist, EC50: 20 nM). GUB03385 has anti-obesity effect .
    GUB03385
  • HY-P11285
    LAGIPRA peptide

    Long acting GIPRA-1

    		 Insulin Receptor Metabolic Disease
    LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes .
    LAGIPRA peptide
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)

    c(RGDfE)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR GLP Receptor Inflammation/Immunology
    GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-126810
    NP213

    		Fungal Infection
    NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections .
    NP213
  • HY-P4047
    Cyclo(RGDfK(Mal))

    		Drug Derivative Others
    Cyclo(RGDfK(Mal)) is a pentapeptide. Cyclo(RGDfK(Mal)) improves the attachment and infiltration of human pluripotent stem cells. Cyclo(RGDfK(Mal)) can be used for 3D stem cell culture and expansion .
    Cyclo(RGDfK(Mal))
  • HY-P5840
    Cyclo(RGDyC)

    		Biochemical Assay Reagents Cancer
    Cyclo(RGDyC) is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo(RGDyC) can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer .
    Cyclo(RGDyC)
  • HY-P4907
    RGD Negative Control

    		Integrin Others
    RGD Negative Control is the negative control of RGD (HY-P0278).
    RGD Negative Control
  • HY-P2092
    Cyclo(L-leucyl-L-tryptophyl)

    Cyclo(Leu-Trp)

    		 Bacterial Fungal Melatonin Receptor Infection Neurological Disease
    Cyclo(L-leucyl-L-tryptophyl) (Cyclo(-Leu-Trp)) is a cyclic dipeptide that inhibits a various of bacteria and fungi. Cyclo(L-leucyl-L-tryptophyl) is a melatonin receptor agonist and is also used as a bitter ligand .
    Cyclo(L-leucyl-L-tryptophyl)
  • HY-W549438
    Cyclo(Phe-Phe)

    		Amino Acid Derivatives Others
    Cyclo(Phe-Phe) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
    Cyclo(Phe-Phe)
  • HY-P1935
    Cyclo(Ala-​Pro)

    		Biochemical Assay Reagents Cancer
    Cyclo(Ala-Pro) is an anticancer agent that is toxic to cancer cells such as A549, HCT-116 and HepG2 .
    Cyclo(Ala-​Pro)
  • HY-P10222
    Cyclo(CRLLIF)

    		HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively .
    Cyclo(CRLLIF)
  • HY-P10304C
    Cyclo(Pro-dArg)

    		Fungal Infection
    Cyclo(Pro-dArg) is an inhibitor of chitinase. Cyclo(Pro-dArg) inhibits the cell separation of Saccharomyces cerevisiae but does not affect its growth. Cyclo(Pro-dArg) inhibits the transition of Candida albicans from yeast to filamentous morphology.
    Cyclo(Pro-dArg)
  • HY-P11271A
    Ribupatide TFA

    		Insulin Receptor GLP Receptor Metabolic Disease
    Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Ribupatide TFA can be studied in antidiabetic research .
    Ribupatide TFA
  • HY-P1676A
    cyclo(RLsKDK) TFA
    2 Publications Verification

    BK-1361 TFA

    		 MMP Cancer
    cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer .
    cyclo(RLsKDK) TFA
  • HY-P0031
    Cyclo(RADfK)
    1 Publications Verification

    		 Integrin Others
    Cyclo(RADfK) can be used as a control for Cyclo(-RGDfK) (HY-P0023) .
    Cyclo(RADfK)
  • HY-P10053
    sPLA2-IIA Inhibitor

    		Phospholipase Metabolic Disease
    sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
    sPLA2-IIA Inhibitor
  • HY-P10965
    Zovaglutide

    ZT002

    		 GLP Receptor Metabolic Disease
    Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .
    Zovaglutide
  • HY-P3472
    Cyclo(IP)

    Cyclo(L-Pro-L-Ile)

    		 Amino Acid Derivatives Inflammation/Immunology
    Cyclo(IP) (Cyclo-(L-Pro-L-Ile)), a Diketopiperazine can be derived From Bacillus thuringiensis JCK-1233, results in suppression of PWD severity and increased the expression of defense-related genes similarly to Bacillus thuringiensis JCK-1233 treatment .
    Cyclo(IP)

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: